Atsena Therapeutics Announces Dosing Complete for Adults in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-Linked Retinoschisis (Globe Newswire)
UF startup Atsena Therapeutics announced that dosing is complete in adults enrolled in Part B of the LIGHTHOUSE study, the Phase I/II/III clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
Atsena Therapeutics Announces Alignment With FDA on Regulatory Pathway to Approval for ATSN-201 in X-Linked Retinoschisis (XLRS)
UF startup Atsena Therapeutics received FDA approval to expand its Phase 1/2 LIGHTHOUSE study of ATSN-201 into a pivotal Phase 1/2/3 trial to support a BLA submission for treating X-linked retinoschisis (XLRS).
Atsena Therapeutics Announces Positive Clinical Data From Part A of Phase I/II Trial Evaluating ATSN-201 Gene Therapy To Treat X-Linked Retinoschisis (XLRS)
UF startup Atsena Therapeutics announced positive clinical data results from Part A of the LIGHTHOUSE study, a Phase I/II clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
Atsena Therapeutics Initiates Part B of Phase I/II Clinical Trial Evaluating Gene Therapy ATSN-201 To Treat X-Linked Retinoschisis
UF startup Atsena Therapeutics, a clinical-stage gene therapy company specializing in genetic medicine to reverse or prevent blindness, has announced the initiation of Part B of the LIGHTHOUSE study, a Phase I/II clinical trial evaluating the subretinal injection of ATSN-201 for treating XLRS.